Matthew Powell, MD

Articles

Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer

November 7th 2024

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Dr Powell on the FDA Approval of Dostarlimab Plus Chemo in Advanced/Recurrent Endometrial Cancer

September 4th 2024

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy in Part 1 of the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

March 29th 2024

Matthew Powell, MD, presents findings from a second interim analysis of part 1 from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial investigating the combination of dostarlimab-gxly plus carboplatin/paclitaxel compared with placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer.

Future Outlook for Treatment of Endometrial Cancer

August 10th 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

Ongoing Trials in Endometrial Cancer

August 10th 2023

An overview of ongoing research in the endometrial cancer treatment space.

KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer

August 3rd 2023

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

The PHAEDRA Study and Clinical Trial Landscape in Endometrial Cancer

August 3rd 2023

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

NRG-GY018 and RUBY Trials in Endometrial Cancer

July 27th 2023

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

Recently Presented Data on Endometrial Cancer

July 27th 2023

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer

July 20th 2023

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer

July 20th 2023

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

July 13th 2023

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Efficacy of Subsequent Therapies in Advanced Ovarian Cancer

July 13th 2023

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer

July 6th 2023

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

Unmet Needs in the Maintenance Setting in Ovarian Cancer

July 6th 2023

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer: Outcomes by Blinded Independent Central Review of the RUBY trial (ENGOT-EN6-NSGO/GOG3031/RUBY)

June 29th 2023

Matthew Powell, MD, presents data from the blinded independent central review of the RUBY trial, which studied dostarlimab in patients with primary advanced or recurrent endometrial cancer.

Ovarian Cancer: Deciding Between Treatment Options

June 29th 2023

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

Frontline Maintenance Therapy in Ovarian Cancer

June 29th 2023

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

Dr. Powell on Tumor Mutational Burden in Ovarian Cancer

October 23rd 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses tumor mutational burden (TMB) in ovarian cancer.

Dr. Powell on the Future of Immunotherapy in Ovarian Cancer

October 5th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses the future of immunotherapy in ovarian cancer.